TNF and rheumatoid arthritis: Dysregulated HDAC activity in RA PBMCs was not affected by conventional anti-TNF therapies whereas treatment with MI192, a HDAC2/3-selective inhibitor, reduced IL6 production in a dose-dependent manner, thus providing a novel therapeutic approach for RA [81].